HCAT vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HCAT exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic 5-year price decline of 98%. While the stock appears cheap on a Price-to-Book (0.29) and Price-to-Sales (0.24) basis, these are 'value traps' given the negative revenue growth (-6.20%) and a massive collapse in YoY EPS (-3300%). The technical trend is completely bearish (0/100), and insider activity is negative, suggesting a lack of confidence from company leadership.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HCAT vs JNJ: Head-to-Head Comparison
This page compares Health Catalyst, Inc. (HCAT) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.